News

Merck to pay $5bn in rofecoxib claims

BMJ 2007; 335 doi: 10.1136/bmj.39398.517176.DB (Published 15 November 2007)
Cite this as: BMJ 2007;335:1011.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Fred Charatan
  1. Florida

    The US drug company Merck announced last week that it will pay $4.85bn (£2.3bn; €3.3bn) to settle 26 600 lawsuits, representing 47 000 plaintiffs, in addition to 265 possible class action cases, arising out of the use of rofecoxib (Vioxx).

    The agreement is to cover cases filed in federal and state courts, and depends on 85% of all plaintiffs dropping their cases. The money will be paid into a settlement fund for claims that qualify. In a …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular